Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD

April Armstrong; Leon Kircik; Ketty Peris; Melinda Gooderham; Sebastien Barbarot; Aleksandra Lesiak; Rie von Eyben; Niels Højsager Bennike; Ann-Marie Tindberg; Margitta Worm

doi:10.25251/26swpe94

April Armstrong

University of California Los Angeles, Los Angeles, CA, USA

Leon Kircik

Icahn School of Medicine at Mount Sinai, New York, NY, USA

Ketty Peris

Università Cattolica del Sacro Cuore, Rome, Italy

Melinda Gooderham

SKiN Centre for Dermatology, Peterborough, ON, Canada

Sebastien Barbarot

University Hospital of Nantes, Nantes, France

Aleksandra Lesiak

Medical University of Lodz, Lodz, Poland

Rie von Eyben

LEO Pharma A/S, Ballerup, Denmark

Niels Højsager Bennike

LEO Pharma A/S, Ballerup, Denmark

Ann-Marie Tindberg

LEO Pharma A/S, Ballerup, Denmark

Margitta Worm

Charité Universitätsmedizin Berlin, Berlin, Germany

Keywords

atopic dermatitis, quality of life, tralokinumab, dosing frequency

Abstract

N/A

References

1. ADBRY (tralokinumab-ldrm). Prescribing information. LEO Pharma A/S; 2024. Accessed September 17, 2025.

2. Adtralza (tralokinumab). Summary of product characteristics (annex I). LEO Pharma A/S; 2025. Accessed September 17, 2025.

3. Simpson, EL, et al. Am J Clin Dermatol. 2023; 24(6):939–952.

4. Silverberg JI, et al. Ann Allergy Asthma Immunol. 2018;121:340-7.

5. Silverberg JI, et al. Br J Dermatol. 2021;184(3):450-463.

6. Wollenberg A, et al. Br J Dermatol. 2021;184(3):437-449.

PDF

Published

2026-03-10

DOI: https://doi.org/10.25251/26swpe94

How to Cite

Reduced Dosing Frequency With Tralokinumab Provides Sustained Improvements in Symptoms and Quality of Life Up to 1 Year in Adults With Moderate-to-Severe AD. J of Skin. 2026;10(2):s731. doi:10.25251/26swpe94

Issue

Vol. 10 No. 2 (2026): March 2026 Issue

Section

Poster Presentations at 2026 Winter Clinical Dermatology Conference®: Atopic Dermatitis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

Melinda Gooderham, Lynda Spelman, Shinichi Imafuku, Marco Romanelli, Joseph F. Merola, April W. Armstrong, Elizabeth Colston, Subhashis Banerjee, Thomas Scharnitz, Andrew Blauvelt, Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23
Linda Stein Gold, Michael Gold, Leon Kircik, Julie Harper, James Del Rosso, Christopher Bunick , Neal Bhatia, Hilary Baldwin, Zoe Draelos, Valerie Callender, Edward Lain , Triple-Combination Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Moderate-to-Severe Acne: Efficacy and Safety Results From a Pooled Phase 3 Analysis , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 1 (2024): January 2024 Issue
Tiffany Mayo, April W Armstrong, Leon Kircik, Jonathan Silverberg, Andrew Blauvelt, Ben Esdalie, Shannon Schneider, Thomas Mark, Melinda Gooderham, Andrew F Alexis, Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Emma Guttman-Yassky, Andrew Blauvelt, Melinda Gooderham, Kenji Kabashima, Marilia Oliveira, Li Xie, Angela Wilson, Carl Dambkowski, Kristine Nograles, Jonathan Silverberg, Half-life-extended Monoclonal Antibody APG777 for Atopic Dermatitis: Design of the Phase 2 APEX Study , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 6 (2024): November 2024 Issue
Emma Guttman-Yassky, Andrew Blauvelt, Melinda Gooderham, Kenji Kabashima, Marilia Oliveira, Li Xie, Angela Wilson, Carl Dambkowski, Kristine Nograles, Jonathan Silverberg, Half-life-extended monoclonal antibody APG777 for atopic dermatitis: Design of the phase 2 APEX study , SKIN The Journal of Cutaneous Medicine: Vol. 9 No. 2 (2025): March 2025 Issue
Linda Stein Gold, Kilian Eyerich, Howard Sofen, Pedro Herranz, Leon Kircik, Tony Bewley, Eric Wolf, Gaia Gallo, Yuxin Ding, Fan Emily Yang, Ignasi Pau-Charles, Melinda Gooderham, Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 6 (2023): November 2023 Issue
Vimal H. Prajapati, Bob Geng, Andrew Blauvelt, Lawrence F. Eichenfield, Parbeer Grewal, Leon Kircik, Peter Lio, Charles Lynde, Eric L. Simpson, Haobo Ren, Daniel Sturm, Grace Wong, Chih-ho Hong, Association Between Early Clinical Responses and Long-Term Outcomes With Ruxolitinib Cream Treatment in Mild to Moderate Atopic Dermatitis , SKIN The Journal of Cutaneous Medicine: Vol. 8 No. 2 (2024): March 2024 Issue
Linda Stein Gold, James Del Rosso, Leon Kircik, Neal D Bhatia, Deirdre Hooper, Walter Nahm, Iain Stuart, Open-Label Extension Study Evaluating the Long-Term Safety, Efficacy, and Tolerability of FMX103 1.5% Topical Minocycline Foam in the Treatment of Moderate-to-Severe Facial Papulopustular Rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Linda Stein Gold, John Selmer, Morten Præstegaard, April Armstrong , Calcipotriene and betamethasone dipropionate cream demonstrates superior efficacy in moderate plaque psoriasis compared to topical suspension: a subgroup analysis of a phase 3 trial , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Leon Kircik, Zoe Draelos, Eric Guenin, Tazarotene 0.045% Lotion for Truncal Acne: Efficacy, Safety, and Spreadability , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 4 (2022): July 2022 Issue

<< < 8 9 10 11 12 13 14 15 16 17 > >>

Main Article Content

Keywords

Abstract

References

Article Sidebar

Article Details

Most read articles by the same author(s)